VYYRF (Voyageur Pharmaceuticals) Debt-to-Asset : 0.01 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

VYYRF Voyageur Pharmaceuticals Ltd VYYRF
28 GF Score
Price $0.12
! 5 Warning Signs
View Full Analysis

What is Voyageur Pharmaceuticals Debt-to-Asset?

Voyageur Pharmaceuticals VYYRF 28 Debt-to-Asset is 0.01 as of May. 2026. GuruFocus rates VYYRF with a GF Score™ of 28/100. The stock has 5 warning signs investors should review.

Voyageur Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2026 was $0.03 Mil. Voyageur Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in May. 2026 was $0.00 Mil. Voyageur Pharmaceuticals's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in May. 2026 was $2.34 Mil. Voyageur Pharmaceuticals's debt to asset for the quarter that ended in May. 2026 was 0.01.

Voyageur Pharmaceuticals  (OTCPK:VYYRF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Voyageur Pharmaceuticals Debt-to-Asset Related Terms

Voyageur Pharmaceuticals Debt-to-Asset Historical Data

* Premium members only.

The historical data trend for Voyageur Pharmaceuticals's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Voyageur Pharmaceuticals Debt-to-Asset Chart

Voyageur Pharmaceuticals Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.00 0.00 0.02 0.01

Voyageur Pharmaceuticals Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

VYYRF vs ZTS: Debt-to-Asset Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyageur Pharmaceuticals Debt-to-Asset vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's Debt-to-Asset falls into.


VYYRF
28GF Score
Voyageur Pharmaceuticals Ltd VYYRF
Debt-to-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Voyageur Pharmaceuticals Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Voyageur Pharmaceuticals's Debt-to-Asset for the fiscal year that ended in Nov. 2025 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 0.028693375416951) / 2.2274007388544
=0.01

Voyageur Pharmaceuticals's Debt-to-Asset for the quarter that ended in May. 2026 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0.029037058545969 + 0) / 2.3356451671446
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Asset →
What does a Debt-to-Asset of 0.01 mean?
Voyageur Pharmaceuticals (VYYRF) has a Debt-to-Asset of 0.01 as of May. 2026. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Voyageur Pharmaceuticals and its competitors.
Is Voyageur Pharmaceuticals' Debt-to-Asset too high?
Voyageur Pharmaceuticals' current Debt-to-Asset is 0.01. Overall, Voyageur Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' Debt-to-Asset compare to ZTS?
Voyageur Pharmaceuticals' Debt-to-Asset of 0.01 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Asset for a Drug Manufacturers company?
A good Debt-to-Asset depends on the Drug Manufacturers industry context. However, Debt-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Asset mean?
A high Debt-to-Asset can signal that a stock is expensive relative to its fundamentals. Debt-to-asset ratio represents the ratio of total debt to total assets. View historical data on Voyageur Pharmaceuticals and its competitors. Voyageur Pharmaceuticals's current Debt-to-Asset is 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current Debt-to-Asset of 0.01. The current Debt-to-Asset is 0.01. Voyageur Pharmaceuticals' overall GF Score™ is 28/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Asset calculated?
Debt-to-Asset is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current Debt-to-Asset is 0.01 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Other Exchanges VM:Canada
Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
28GF Score

Get the complete analysis for VYYRF

Debt-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.12
Price